MEGGLE Excipients & Technology presenting new InhaLac® DPI products online at DDL 2020

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) will be a prominent presence at the 2020 Drug Delivery to the Lungs (DDL) Conference, this year presented as a virtual event on account of the COVID-19 pandemic.

This will be MEGGLE’s eighth successive appearance at the DDL conference, reflecting its commitment to the DPI sector with its sieved, milled and micronized InhaLac® grade lactose monohydrate products.

MEGGLE virtual booth

MEGGLE will have a virtual booth at DDL’s online Industry Exhibition Hall, hosting live online and video chats as well as public presentations.

“We are proud to continue our long association with the DDL conference and The Aerosol Society that has seen us as a regular presenter of scientific poster and Silver Sponsor of the event,” commented Dr. Mirjam Kobler, Head of MEGGLE R&D.

InhaLac® DPI portfolio

Dr. Kobler will represent MEGGLE at the event, along with Dr. Sabine Friedlhuber, Application Manager for DPI products.

“We will be able to present details and application advice for our extensive portfolio, as well as opportunities for customized products,” said Dr. Friedlhuber.

The DDL MEGGLE microsite will present details of the InhaLac® portfolio with particular emphasis on recently launched products InhaLac® 140, InhaLac® 150 and 500, along with a DPI video and plentiful resource, including downloadable documents and FAQ answers.

Networking opportunities

“These new milled products form very useful extensions of our milled inhalative lactose portfolio, offering excellent stability, flowability, particle size distribution and 24 month retest intervals,” said Dr. Mirjam Kobler.

MEGGLE will also be an active participant in the virtual networking lounge that forms part of the DDL 2020 offer.

About MEGGLE Wasserburg

Bavarian-based MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About DDL 2020

The Drug Delivery to the Lungs Conference (DDL) is Europe’s premier conference dedicated to pulmonary and nasal drug delivery.

Originally due to be staged in Edinburgh, DDL 2020 will now be delivered virtually as a three-day online event, opening December 9.

DDL2020 will feature a series of Christmas Lectures focusing on recent inhalation therapy developments that will also provide a forum for scientific discussion.

It will also allow FLASH presentation of Abstract Submissions for consideration by the scientific review committee as well as pre-recorded presentations covering a variety of inhalation therapy topics.

The online discussion forum will be open following daily s lectures and there will be a virtual Industry Exhibition Hall, where DDL sponsors can interact with visitors via live video and text chat.

In Line with the Aerosol Society’s charter, DDL2020 will not be a commercial event, with registration and lecture access free to all. Further information at https://ddl-conference.com/ddl2020

Resources

Click Optimising  DPI  formulations  –  The  influence  of  surface energy on the suitability of additional fines – to review the Scientific Paper Poster together with University Kiel.
Click Influence of the opening size on the air velocity through the capsule in the capsule based DPI’s – to review the Scientific Paper Poster together with RCPE .
Click on Register for DDL 2002 for free registration page.